Objective: Fever of unknown origin continues to be a diagnostic challenge for clinicians. The aim of this study was to confirm whether (18)F-fluorodeoxyglucose ((18)F-FDG)-PET/computed tomography (CT) is a helpful tool in patients suffering from this condition.
Patients And Methods: Fifty-seven patients with fever of unknown origin were examined with (18)F-FDG-PET/CT as part of their diagnostic workup at the clinicians' discretion. The medical records were read retrospectively to establish the final diagnosis and evaluate the degree to which PET/CT contributed to the diagnosis.
Results: The examination was considered helpful if it corresponded to the final diagnosis by showing uptake in an organ considered responsible for the condition, or if it was without focal findings, thereby excluding the patient from having focal infection or malignancy. It was perceived false positive if it pointed towards an organ not regarded by the clinicians as being related to the final diagnosis. It was perceived not helpful if the cause of fever was not visible on (18)F-FDG-PET/CT. We found (18)F-FDG-PET/CT helpful in 75% of patients, not helpful in 4%, and false positive in 21% of patients.
Conclusion: (18)F-FDG-PET/CT is a useful tool in the investigation of fever of unknown origin; it can reduce patient inconvenience and possibly costs to society if used earlier in the diagnostic process.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MNM.0000000000000146 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hemophagocytic Lymphohistiocytosis in a Kidney Transplant Recipient: Case Report.
Transplant Proc
January 2025
Nephrology, Hospital Universitario Donostia, San Sebastián, España.
Hemophagocytic lymphohistiocytosis is a potentially fatal multisystemic inflammatory syndrome that is better understood in the pediatric population. Consequently, the diagnostic criteria for adults still derives from studies conducted in the pediatric population. Several genetic mutations and secondary causes, including infections, autoimmunity, and malignancy, have been reported as significant actors in this condition, especially in adults.
View Article and Find Full Text PDFClinical features, treatment, and prognosis of pembrolizumab -induced Stevens-Johnson syndrome / toxic epidermal necrolysis.
Invest New Drugs
January 2025
College of Pharmacy, Changsha Medical University, No. 1501 Leifeng Avenue, Xiangjiang New District, Changsha, Hunan, 410219, China.
The understanding of pembrolizumab-induced Stevens-Johnson syndrome (SJS) /toxic epidermal necrolysis (TEN) primarily derives from case reports, leaving specific clinical features largely unknown. This study aims to investigate the clinical characteristics associated with pembrolizumab-induced SJS/TEN and to encourage the judicious use of pembrolizumab. Retrieve reports on pembrolizumab induced SJS/TEN before September 30, 2024 for retrospective analysis.
View Article and Find Full Text PDFTravel-related health problems in travellers admitted at the University Centre of Maritime and Tropical Medicine in Poland, 2023.
Int Marit Health
January 2025
Department of Tropical Medicine and Epidemiology, Institute of Maritime and Tropical Medicine, Medical University of Gdańsk, Poland.
Background: Meta-analyses show that 43-79% of international travellers develop a travel-related health problems during or after journey. The aim of the present research was to analyse travel-related morbidity in travellers hospitalized at the University Centre of Maritime and Tropical Medicine in Gdynia, Poland.
Material And Methods: This retrospective study was based on the analysis of medical records of 159 Polish patients hospitalized at the Department of Tropical and Parasitic Diseases between January and December 2023.
[Clinical Characteristics and Risk Factors of Infection in Hospitalized Patients with Multiple Myeloma with New Generation Therapies].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
December 2024
The Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital,Taiyuan 030000, Shanxi Province, China.
Article Synopsis
- The study aimed to assess infection risks and characteristics in multiple myeloma patients receiving new therapies, involving 155 patients from a hospital over 5 years.
- The analysis identified 242 infection episodes, predominantly clinically defined infections, with lower respiratory tract being the most affected area.
- Key risk factors for developing infections included having advanced disease (ISS stage III), receiving multiple lines of treatment, and being frail.
In vitro to clinical efficacy: Neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 strains.
J Infect Chemother
December 2024
Department of Infectious Diseases, Hiroshima University Hospital, 1-2-3 Kasumi, Minamiku, Hiroshima 734-8551, Japan. Electronic address:
Introduction: Neutralizing antibodies have been approved for coronavirus disease 2019 (COVID-19) treatment; however, no study has clarified the link among their neutralizing effect in vitro, the period of infectious virus shedding, and symptoms in the acute phase. Here, we aimed to assess the duration of virus shed and fever in patients with mild COVID-19 stratified by their characteristics and type of neutralizing antibody administered.
Methods: We evaluated the efficacy of neutralizing antibodies in terms of the duration of infectious virus excretion and fever in three groups: patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta strain treated with REGEN-CoV2 (REGN-CoV2 group) and patients infected with Omicron strain treated with S309 (S309 group) or untreated (untreated group).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!